Studies tumor DNA in blood as a marker in Hodgkin lymphoma
Looks at tumor DNA in blood of adults with Hodgkin lymphoma.
Plain-language title generated from the registry record
Registry title: Prognostic Significance of ctDNA in HL
Key facts
- Where
- Hradec Králové, Olomouc, and Prague, CzechiaSee the 5 sites
Where in Czechia
- University Hospital Hradec KraloveHradec Králové, CzechiaTaking people
- University Hospital OlomoucOlomouc, CzechiaTaking people
- General University HospitalPrague, CzechiaTaking people
- University Hospital Kralovske VinohradyPrague, CzechiaTaking people
- Charles UniversityPrague, CzechiaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Interni hematologicka klinika FNKV
- Trial code
- NCT06263530
- Record updated
- 16 February 2024
- Original description
Specific somatic mutations using ctDNA will be analyzed in predefined subgroups of cHL (e.g., age <60 and ≥ 60 years, EBV). These mutations will be correlated with response to the treatment in the first line, in the relapse, during brentuximab vedotin and/or nivolumab treatment. Circulating tumor DNA will be correlated with the extent of tumor mass and chemo/radiotherapy.Read full original descriptionShow less
Prognostic Significance of Circulating Tumor DNA in Hodgkin Lymphoma
Specific somatic mutations using ctDNA will be analyzed in predefined subgroups of cHL (e.g., age <60 and ≥ 60 years, EBV). These mutations will be correlated with response to the treatment in the first line, in the relapse, during brentuximab vedotin and/or nivolumab treatment. Circulating tumor DNA will be correlated with the extent of tumor mass and chemo/radiotherapy.
Inclusion: Patients ≥ 18 years with newly histologically confirmed classical Hodgkin lymphoma (cHL) will be enrolled; signing the informed consent.
Exclusion: Pacients without signing the informed consent.